Global Bladder Cancer Therapeutics Market was Valued USD 4.06 Bn in 2022, with an Estimated CAGR of 9.5% (2023- 2031) 

Bladder cancer is one of the ten most frequent diseases worldwide, causing significant morbidity and death and hence imposing a significant burden on health-care systems. Bladder cancer incidence is influenced by demographic changes, most notably population growth and ageing, as well as exposure to risk factors, particularly tobacco smoking.

In the last decade, bladder cancer treatment market has witnessed substantial development in the form of targeted medicines and minimally invasive surgical procedures, as well as new research revealing the prospect for avoiding surgery entirely using neoadjuvant therapy.

Global Bladder Cancer Therapeutics Market Revenue & Forecast, (US$ Million), 2015 – 2031Factors Propelling the Global Bladder Cancer Therapeutics Market

Researchers are attempting to increase the knowledge of bladder cancer treatment. Bladder cancer treatment has the potential to become more successful and less hazardous as a result of recent advancements in immunotherapy and targeted therapy. Several immunotherapy drugs, all of which are immune checkpoint inhibitors, have been authorised in recent years for the treatment of some patients with locally advanced or metastatic bladder cancer.

Immune checkpoint inhibitors are currently being tested in the early stages of bladder cancer and in conjunction with other therapies such as chemotherapy. Recently The Food and Drug Administration (FDA) authorised nivolumab (Opdivo) as an additional (adjuvant) therapy for patients with urothelial carcinoma who are at high risk of recurrence following surgery for the illness in 2021. This was the first FDA-approved therapy for people with this form of cancer. According to revised study findings published in 2023, patients who got nivolumab had a median disease-free survival of 22 months, compared to around 11 months for those who received a placebo. Thus, these advancements in the treatments and timely regulatory approval will boost the growth of the global bladder cancer therapeutics market.

Nonmuscle invasive bladder cancer, muscle-invasive bladder cancer, and metastatic bladder cancer are the major types of bladder cancer tumours. In 2022, three-quarters of patients were reported to have tumours contained in the superficial layers lining the bladder (nonmuscle invasive), which may be controlled with a mix of IV medicines, procedures to shave off the tumour, and pharmaceuticals used within the bladder to treat the cancer. Approximately half of all bladder cancers are discovered in the early, non-muscle invasive stage (stage 0-I), which means that cancer cells are only found within the bladder wall’s inner layer. As with many malignancies, early detection increases the likelihood of survival.

Report Coverage and Deliverables: 

A third of cases are identified when the disease has progressed further inside the bladder, a condition known as muscle-invasive bladder cancer (stages II and III). The disease has progressed to adjacent muscles and organs in the remaining patients, resulting in metastatic Treatment for muscle-invasive illness includes chemotherapy followed by bladder removal surgery. Chemotherapy is demanding, and for many individuals, it is not an option due to other medical issues. The procedure can also be complicated, making it unsafe for older people. Thus stage-based bladder cancer treatment is necessary to provide the most effective and appropriate care to individuals diagnosed with bladder cancer.

Bladder cancer is one of Europe’s top five most frequent cancers, taking about 67,000 lives each year. According to a recent survey conducted by the European Association of Urology (EAU), Europe has some of the highest incidence rates of bladder cancer in the world, yet understanding of the condition is still extremely low. Thus healthcare organizations along with market players have been actively involved in research and advancements in bladder cancer therapeutics. European researchers were working on identifying and validating biomarkers and genetic markers specific to bladder cancer in European populations. Thus in the upcoming years, Europe region will have potential for the growth of bladder cancer therapeutics market.

Competitive Landscape

The competitive landscape of the bladder cancer therapeutics market is robust and involves several pharmaceutical companies, biotechnology firms, and research institutions. Companies in this space are continually working to develop and market innovative therapies for bladder cancer. The report offers an in-depth analysis of the competitive landscape which is further influenced by emerging trends, evolving customer demands, strategic partnerships, and acquisitions, making it a dynamic and evolving market.

Leading players operating in the global bladder cancer therapeutics market are:

• Abbott
• AbbVie
• Bristol-Myers Squibb
• Eli Lilly and Company
• Ferring B.V.
• GSK plc
• Hikma Pharmaceuticals PLC
• Johnson & Johnson Services, Inc.
• Merck & Co., Inc.
• Pacific Edge
• Pfizer Inc
• Seagen Inc
• UroGen Pharma, Inc.
• Other market participants

Global Bladder Cancer Therapeutics Market Report Coverage

Global Bladder Cancer Therapeutics MarketBy Cancer Type

• Non muscle invasive bladder cancer
• Muscle invasive bladder cancer
• Transitional cell bladder cancer (urothelial carcinoma)
  • Papillary carcinoma
  • Flat carcinomas
• Metastatic bladder cancer
• Recurrent bladder cancer
• Squamous Cell Bladder Cancer
• Others

By Treatment Type

• Surgery
  • Transurethral resection (TUR) with fulguration
  • Partial cystectomy
  • Radical cystectomy with urinary diversion
• Chemotherapy
• Immunotherapy
• Targeted therapy
• Gene therapy
• Radiation therapy
• Others

By Stage

• Stage 0
  • Stage 0a
  • Stage 0is
• Stage I
• Stage II
• Stage III
• Stage IV
  • Stage IVA
  • Stage IVB
• Recurrent

By Diagnosis

• Cystoscopy
• Bladder Ultrasound
• Urinalysis
• Biopsy
• Others

By Gender

• Male
• Female

By Treatment Channel

• Public
• Private

By Region

• North America (U.S., Canada, Mexico, Rest of North America)
• Europe (France, The UK, Spain, Germany, Italy, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, The Netherlands, Luxembourg), Rest of Europe)
• Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Rest of Asia Pacific)
• Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa)
• Latin America (Brazil, Argentina, Rest of Latin America)

Table of Contents

.